Boehringer Ingelheim to acquire NBE-Therapeutics for €1.18bn
Boehringer Ingelheim has agreed to acquire NBE-Therapeutics, a Switzerland-based clinical-stage biotechnology company, in a deal valued at €1.18bn. NBE-Therapeutics is developing antibody-drug conjugates and targeted cancer therapies derived